1288 Pear Avenue Mountain View, CA 94043
Phone: 650-210-1200 www.aclara.com

Joseph Limber, president and CEO NASDAQ:ACLA


Founded in 1995, Aclara works in the fields of microfluidics, microfabrication, genomics and proteomics. It is applying advances in microfluidics and miniaturization to genetic analysis, drug screening and optimization, and clinical diagnostics. The company specializes in lab-on-a-chip technologies.

Aclara’s microfluidic devices use a novel 96-channel design that enables the miniaturization of biochemical assays to nanoliter volumes. Aclara’s eTag assay chemistry enables concurrent gene expression, protein expression and protein function analyses from the same sample. And, Plurex Multiplexing System is a spatial and chemical multiplexing system for genotyping sample preparation used in SNP analysis.

The company raised $189 million in its initial public offering in March 2000.


In October 2001, Aclara and Third Wave Technologies Inc., of Madison, Wis., announced they will collaborate in the development and commercialization of multiplexed gene expression research products. In January 2002, Aclara said it is collaborating with P.J. Utz and William Robinson, both at the Stanford University School of Medicine, to apply Aclara's eTag technology to proteomics research.